Form 4: Context Therapeutics CFO Acquires Stock Options

Jennifer Lynn Minai-Azary, CFO of Context Therapeutics, reports the acquisition of stock options exercisable for 371,800 shares of common stock.

Summary

• Jennifer Lynn Minai-Azary, the Chief Financial Officer of Context Therapeutics Inc., filed a Form 4 on February 14, 2025.
• The form reports a transaction that occurred on February 13, 2025, where she acquired stock options.
• These options grant her the right to buy 371,800 shares of Context Therapeutics' common stock at an exercise price of $0.81 per share.
• The options vest over a four-year period, with 25% vesting on February 13, 2026, and the remainder vesting in equal monthly installments over the following three years, contingent upon continued service with the company.
• Following this transaction, Minai-Azary directly owns derivative securities consisting of options for 371,800 shares.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing an executive's stock option acquisition. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder confidence as it shows the CFO's commitment to the company's future.

Key Dates